129 related articles for article (PubMed ID: 36634582)
1. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment.
Ting A; Story T; Lecomte C; Estrin A; Syed S; Lee E
J Neurol Sci; 2023 Feb; 445():120531. PubMed ID: 36634582
[TBL] [Abstract][Full Text] [Related]
2. Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States.
Parthan A; Royston M; Thanataveerat A; East EL; Parzynski CS; Habib AA
Muscle Nerve; 2024 Feb; 69(2):157-165. PubMed ID: 38018505
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data.
Pisc J; Ting A; Skornicki M; Sinno O; Lee E
J Comp Eff Res; 2024 Jan; 13(1):e230108. PubMed ID: 38099519
[No Abstract] [Full Text] [Related]
4. Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States.
Qi CZ; Hughes T; Gelinas D; Li Y; Goyal A; Brauer E; Bhuwalka A; Sato M; Jadhav S; Phillips G
J Neurol Sci; 2022 Dec; 443():120480. PubMed ID: 36347174
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.
Zhdanava M; Pesa J; Boonmak P; Cai Q; Pilon D; Choudhry Z; Souayah N
Curr Med Res Opin; 2024 Jul; 40(7):1145-1153. PubMed ID: 38745448
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka KV
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns in myasthenia gravis: A United States health claims analysis.
Mahic M; Bozorg A; Rudnik J; Zaremba P; Scowcroft A
Muscle Nerve; 2023 Apr; 67(4):297-305. PubMed ID: 36721910
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
[TBL] [Abstract][Full Text] [Related]
10. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.
Guptill JT; Runken MC; Eaddy M; Lunacsek O; Fuldeore RM
Am Health Drug Benefits; 2019 May; 12(3):127-135. PubMed ID: 31346365
[TBL] [Abstract][Full Text] [Related]
12. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.
Furlan JC; Barth D; Barnett C; Bril V
Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis.
Sorgun MH; Sener HO; Yucesan C; Yucemen N
Neurol Sci; 2014 Jun; 35(6):891-6. PubMed ID: 24399309
[TBL] [Abstract][Full Text] [Related]
14. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy.
Antonini G; Habetswallner F; Inghilleri M; Mantegazza R; Rodolico C; Saccà F; Sgarzi M; deRuyck F; Paci S; Phillips G; Crippa L; Veronesi C; Perrone V; Degli Esposti L;
Heliyon; 2023 Jun; 9(6):e16367. PubMed ID: 37274644
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of myasthenia gravis from a large U.S. insurance database.
Guptill JT; Marano A; Krueger A; Sanders DB
Muscle Nerve; 2011 Dec; 44(6):907-11. PubMed ID: 22102461
[TBL] [Abstract][Full Text] [Related]
17. Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.
Phillips G; Abreu C; Goyal A; Li Y; Whangbo A; Gelinas D; Brauer E; Bhattacharya S
Front Neurol; 2021; 12():809999. PubMed ID: 35115997
[TBL] [Abstract][Full Text] [Related]
18. Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
Wilf-Yarkoni A; Lotan I; Steiner I; Hellmann MA
J Neurol; 2021 Oct; 268(10):3871-3877. PubMed ID: 33829320
[TBL] [Abstract][Full Text] [Related]
19. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
[No Abstract] [Full Text] [Related]
20. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
